Anika Therapeutics (NASDAQ:ANIK) Issues Earnings Results

Anika Therapeutics (NASDAQ:ANIK) issued its quarterly earnings data on Wednesday. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.27, Zacks reports. Anika Therapeutics had a negative net margin of 9.52% and a negative return on equity of 5.90%.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Strong second-quarter performance: Revenue rose 16% to $32.6 million, commercial-channel revenue increased 17%, and adjusted EBITDA reached $7.1 million, the company’s highest quarterly level since 2020.
• Guidance was raised: Anika now expects 2026 total revenue growth of 5%–10%, commercial-channel growth of 12%–18%, OEM growth of 0%–5%, and an adjusted EBITDA margin of 13%–17%.
• Operational improvements are lifting profitability: Gross margin expanded to 65%, supported by manufacturing productivity, better yields, increased throughput, favorable mix, and lean initiatives; management expects margins to remain around 64% or higher in the second half.
• International OA pain-management products and regenerative solutions remained growth drivers, with Cingal up 32%, Monovisc up 24%, and Integrity year-to-date sales up approximately 39% in the quarter.
• Regulatory timing remains uncertain: Hyalofast’s FDA review is continuing after a deficiency letter, while 2027 guidance excludes the previously expected $3 million of U.S. Hyalofast revenue; management also expects second-half profitability to be lower due to OEM order timing and continued pricing pressure.

Anika Therapeutics Stock Performance

Anika Therapeutics stock traded up $1.35 during midday trading on Wednesday, hitting $16.50. 66,576 shares of the company’s stock were exchanged, compared to its average volume of 113,572. The stock has a market cap of $219.62 million, a price-to-earnings ratio of -20.89 and a beta of 0.23. Anika Therapeutics has a 12-month low of $7.87 and a 12-month high of $17.75. The firm’s 50 day simple moving average is $14.99 and its 200 day simple moving average is $13.61.

Analyst Ratings Changes

ANIK has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anika Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut shares of Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Anika Therapeutics currently has a consensus rating of “Hold” and an average target price of $17.00.

Insider Transactions at Anika Therapeutics

In other Anika Therapeutics news, Director John B. Henneman III bought 5,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average price of $14.66 per share, for a total transaction of $73,300.00. Following the completion of the purchase, the director owned 54,871 shares of the company’s stock, valued at approximately $804,408.86. This represents a 10.03% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Stephen D. Griffin bought 12,200 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were acquired at an average price of $12.29 per share, with a total value of $149,938.00. Following the purchase, the chief executive officer directly owned 36,163 shares of the company’s stock, valued at approximately $444,443.27. This trade represents a 50.91% increase in their position. The SEC filing for this purchase provides additional information. 12.08% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Corient Private Wealth LLC increased its holdings in shares of Anika Therapeutics by 4.3% in the fourth quarter. Corient Private Wealth LLC now owns 32,224 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 1,324 shares during the period. Invesco Ltd. increased its stake in Anika Therapeutics by 7.9% in the 4th quarter. Invesco Ltd. now owns 25,272 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 1,843 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in Anika Therapeutics during the 4th quarter worth $122,000. NewEdge Advisors LLC acquired a new stake in shares of Anika Therapeutics in the 4th quarter worth $139,000. Finally, XTX Topco Ltd boosted its holdings in shares of Anika Therapeutics by 74.3% in the fourth quarter. XTX Topco Ltd now owns 22,252 shares of the biotechnology company’s stock valued at $214,000 after acquiring an additional 9,482 shares in the last quarter. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.